Authors:
MALERCZYK C
FUCHS B
BELZ GG
ROLL S
BUTZER R
BREITHAUPTGROGLER K
HERRMANN V
MAGIN SG
HOGEMANN A
VOITH B
MUTSCHLER E
Citation: C. Malerczyk et al., ANGIOTENSIN-II ANTAGONISM AND PLASMA RADIORECEPTOR-KINETICS OF CANDESARTAN IN MAN, British journal of clinical pharmacology, 45(6), 1998, pp. 567-573
Authors:
HOOGKAMER JFW
KLEINBLOESEM CH
OUWERKERK M
HOGEMANN A
NOKHODIAN A
KIRCH W
WEIDEKAMM E
Citation: Jfw. Hoogkamer et al., PHARMACOKINETICS AND SAFETY OF CANDESARTAN CILEXETIL IN SUBJECTS WITHNORMAL AND IMPAIRED LIVER-FUNCTION, European Journal of Clinical Pharmacology, 54(4), 1998, pp. 341-345
Authors:
MEINEKE I
FELTKAMP H
HOGEMANN A
GUNDERTREMY U
Citation: I. Meineke et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF CANDESARTAN AFTER ADMINISTRATION OF ITS PRO-DRUG CANDESARTAN CILEXETIL IN PATIENTS WITH MILD-TO-MODERATE ESSENTIAL-HYPERTENSION - A POPULATION ANALYSIS, European Journal of Clinical Pharmacology, 53(3-4), 1997, pp. 221-228
Authors:
DINGEMANSE J
KLEINBLOESEM CH
HOOGKAMER JFW
OUWERKERK M
HOGEMANN A
NOKHODIAN A
Citation: J. Dingemanse et al., COMPARATIVE PHARMACOKINETICS OF MULTIPLE-DOSE CANDESARTAN IN SUBJECTSWITH AND WITHOUT IMPAIRED HEPATIC-FUNCTION, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 61-61